Vehicle (SD-101 0%)

DRUG2 trials

Sponsors

Scioderm, Inc., Paradigm Therapeutics

Conditions

Epidermolysis BullosaEpidermolysis Bullosa (EB)

Phase 2

Study of Effectiveness and Safety of SD-101 in Participants With Epidermolysis Bullosa

CompletedNCT02014376

Scioderm, Inc.Epidermolysis Bullosa

Start: 2014-01-06End: 2014-06-24Updated: 2020-01-13

Phase 3

Efficacy and Safety Study to Evaluate SD-101 in Epidermolysis Bullosa

RecruitingNCT07482787

Paradigm TherapeuticsEpidermolysis Bullosa (EB)

Start: 2026-07-21End: 2027-06-17Target: 80Updated: 2026-09-04

Related Papers

Efficacy and tolerability of the investigational topical cream SD-101 (6% allantoin) in patients with epidermolysis bullosa: a phase 3, randomized, double-blind, vehicle-controlled trial (ESSENCE study).

2020-06-2313 citations